Fiscal impact reports (FIRs) are prepared by the Legislative Finance Committee (LFC) for standing finance
committees of the NM Legislature. The LFC does not assume responsibility for the accuracy of these reports
if they are used for other purposes.
Current FIRs (in HTML & Adobe PDF formats) are a vailable on the NM Legislative Website (legis.state.nm.us).
Adobe PDF versions include all attachments, whereas HTML versions may not. Previously issued FIRs and
attachments may be obtained from the LFC in Suite 101 of the State Capitol Building North.
F I S C A L I M P A C T R E P O R T
SPONSOR
Carraro
ORIGINAL DATE
LAST UPDATED
01/29/08
HB
SHORT TITLE
Study Antidepressants and Suicide
SM 9
ANALYST Hanika-Ortiz
ESTIMATED ADDITIONAL OPERATING BUDGET IMPACT (dollars in thousands)
FY08
FY09
FY10 3 Year
Total Cost
Recurring
or Non-Rec
Fund
Affected
Total
$0.1
Recurring General
Fund
(Parenthesis ( ) Indicate Expenditure Decreases)
SOURCES OF INFORMATION
LFC Files
Responses Received From
Department of Health (DOH)
Health Policy Commission (HPC)
Regulation and Licensing Department (RLD)
SUMMARY
Synopsis of Bill
Senate Memorial 9 requests the Health Policy Commission convene an expert task force to study
the correlation between antidepressant use and suicidal thoughts and behaviors and to
recommend solutions to address any correlation.
If a correlation exists, the task force will further examine; (1) mandatory continuing medical
education courses for providers who treat and prescribe for depression in the young; (2) allowing
the prescribing of antidepressants only in conjunction with concurrent psychotherapy; and (3)
allowing only providers who specialize in psychiatric practice to prescribe psychotropic
medications.
FISCAL IMPLICATIONS
This study or investigation could become very costly to conduct and there is no appropriation
identified to support this effort. The task force will be required to bring in experts from many
different backgrounds, including the national research community, to provide expertise on
whether a correlation exists and provide recommendations for best practice in the area of
antidepressant pharmaceutical use in children and adolescents.